Fertility and Ovarian Reserve in Female Childhood Cancer Survivors

NCT ID: NCT06626282

Last Updated: 2024-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

340 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-09

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A. Objectives:

In a cohort of female survivors of paediatric cancer aged of at least 18 years old at the time of evaluation, the main objectives of the project PRINCESS are:

1. to evaluate the impact of low-intermediate dose alkylating agents on ovarian function and fertility;
2. to assess the impact of ovarian tissue cryopreservation, used as fertility preservation technique, on further ovarian function and fertility;
3. to identify new screening tools of premature ovarian insufficiency, using targeted and whole genome methylation techniques.

B. Project Design:

The complementarity of the promoters 'and co-applicants skills allows the building of a national translational team which relies on the pre-clinical, clinical and research expertise of paediatric oncologists (Drs Dedeken, De Ville de Goyet and Piette), endocrinologist (Dre Parent) and gynaecologists (Drs Demeestere, Dolmans, Henry and Jadoul). The promoter and co-promotor will directly supervise Dr Bianca David (PhD student) who will contribute to all aspects of the research. The PhD student will be hosted in the LBTD/GIGA-Cancer/Neurosciences and will benefit from its infrastructure, the help of technicians and the expertise of the AS Parent team for epigenetic studies.

Participants eligible to participate to the PRINCESS project (n=170) and controls (n=170) will be invited by a coordinating nurse to take part to PRINCESS fertility evaluation in the medically assisted reproduction centre of one of the three participating institutions. During the first consultation, the PRINCESS project will be explained to the participants, who will sign an informed consent. The expert, with the help of the coordinating nurse, will present the PRINCESS questionnaire including information about their fertility and parenthood situation to the participant, who will then complete it in privacy. A second consultation will take place after minimum 6 weeks without hormonal contraception and ideally between day 2-5 of the menstrual cycle. During this consultation, clinical, biological and ultrasound evaluations will be performed (see below, data collection). A third consultation will be organized to inform he participants of their results. Participants will be offered a compensation for participating to the study.

C. Data collection

1. Data extracted from the Paediatrics Late Effects project at first paediatric cancer and/or relapse(s) and/or progression(s) and/or second cancer(s)

* Type of cancer
* Dates of diagnosis and end of treatment
* Treatment details (type and doses of chemotherapy, type and field of radiotherapy, type of surgery, stem cell transplantation)
* Fertility preservation measures
* Relevant late effects (endocrine, gynaecology, etc.), defined following the Common Terminology Criteria for Adverse Events, version 4.03 (2010-06-14).
* Vital status at last news
2. Data collected during PRINCESS fertility evaluation

* Height, weight, body mass index
* Puberty history, date of menarche and menstrual cycles history
* Pregnancies, childbirth, use of hormonal therapies, including contraception,
* Menopause substitutive hormonal treatment
* Measurement of LH, FSH, oestradiol, progesterone, prolactin, TSH, T4, AMH levels
* Evaluation of the ovarian reserve by ultra-sound (antral follicle count).

Note: one blood EDTA tube will be collected from each patient and stored in a bio-bank in CHU of Liege for later epigenetics analysis.

Data collected by PRINCESS questionnaire Marital status Lifestyle (tobacco/cannabis/alcohol consumption) Level of education Occupation For children and adolescent female cancer survivors who ever tried to become pregnant: use of medical help (and type), pregnancy course (live birth with or without birth defect, miscarriage, medical abortion, stillbirth)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Childhood Cancer Survivors Fertility Ovarian Reserve CED Ovarian Reserve Markers Cryopreservation Alkylating Agents Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Child and adolescent female patients included in the Paediatrics Late Effects Project:
* diagnosed with cancer1 between 01/01/2004 and 31/12/2018
* \<17 years old at diagnosis
* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF
* alive
* ≥ 18 years-old at time of recruitment.

Exclusion Criteria

* Cancer diagnosis for controls
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

La Fondation contre le cancer, Belgique

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire de Liege

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bianca David

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital de la Citadelle

Liège, Wallonia, Belgium

Site Status RECRUITING

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status NOT_YET_RECRUITING

HUDERF

Brussels, , Belgium

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bianca David, MD

Role: CONTACT

32 4 321 87 39

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bianca David, MD

Role: primary

32 4 321 87 39

Anne Lambert

Role: backup

Sabine Devaux

Role: primary

+ 32 2 764 23 50

Sarah Wambacq

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023/388

Identifier Type: OTHER

Identifier Source: secondary_id

B7072023000101

Identifier Type: OTHER

Identifier Source: secondary_id

OST 2022/2173

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Childhood Cancer Survivor Study
NCT01120353 RECRUITING